VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells
- 1 July 2001
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 68 (1) , 55-64
- https://doi.org/10.1023/a:1017994722130
Abstract
The effects of vasoactive intestinal peptide (VIP) antagonists on breast cancer cells were investigated. (N-stearyl, norleucine17)VIP hybrid ((SN)VIPhyb) inhibited specific 125I-VIP binding to MCF7,...Keywords
This publication has 26 references indexed in Scilit:
- Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin‐like growth factor‐I in human mammary epithelial cellsJournal of Cellular Physiology, 1995
- Multiple receptors for PACAP and VIPTrends in Pharmacological Sciences, 1994
- EGF receptor expression, regulation, and function in breast cancerBreast Cancer Research and Treatment, 1994
- Differential signal transduction by five splice variants of the PACAP receptorNature, 1993
- Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.Proceedings of the National Academy of Sciences, 1993
- A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.Proceedings of the National Academy of Sciences, 1993
- A signal chain of eventsNature, 1992
- Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptideNeuron, 1992
- Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell linesPeptides, 1990
- Polypeptide with Broad Biological Activity: Isolation from Small IntestineScience, 1970